SARA HUSSAINI: Open Payments
NPI 1134644057 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$570 in 25 payments from 11 companies in 2025. Trend: 2023 $159 · 2024 $454 · 2025 $570
Food & beverage: $570
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 3 | $166 |
| ABBVIE INC. | 9 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Celltrion USA Inc. | 2 | $45 |
| Janssen Biotech, Inc. | 2 | $39 |
| Intercept Pharmaceuticals, Inc. | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
| Braintree Laboratories, Inc. | 1 | $20 |
| VIVUS LLC | 1 | $20 |
| Ardelyx, Inc. | 1 | $17 |
Products named: DUPIXENT, ENTYVIO, VEGZELMA, RINVOQ, TREMFYA, CREON, LINZESS, SKYRIZI.
Industry payments across FL — which companies pay providers there.
